Rosenstein, who holds a Ph.D from Duke University, focuses on free radicals. His goal is to develop a model that will allow chemists to carry out free radical reactions to form a preponderance of one stereoisomeric product. With the methodology he is currently creating, Rosenstein would be able to efficiently produce the single stereoisomer that is effective in pharmaceutical medications.He has published articles in Tetrahedron Letters, Synthetic Communications, and the Journal of Chemical Education. He has received grants from several agencies such as the American Chemical Society/ Petroleum Research Fund and the National Science Foundation. He is a member of the American Chemical Society, Phi Lambda Upsilon, the Council on Undergraduate Research, and Sigma Xi.